These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

290 related articles for article (PubMed ID: 22086890)

  • 1. Time for changes in pneumococcal vaccination of adults?
    Overman MC
    J Am Osteopath Assoc; 2011 Oct; 111(10 Suppl 6):S19-22. PubMed ID: 22086890
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Invasive pneumococcal disease in young children before licensure of 13-valent pneumococcal conjugate vaccine - United States, 2007.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2010 Mar; 59(9):253-7. PubMed ID: 20224541
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recommendations for the prevention of Streptococcus pneumoniae infections in infants and children: use of 13-valent pneumococcal conjugate vaccine (PCV13) and pneumococcal polysaccharide vaccine (PPSV23).
    American Academy of Pediatrics Committee on Infectious Diseases
    Pediatrics; 2010 Jul; 126(1):186-90. PubMed ID: 20498180
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Invasive pneumococcal disease in children 5 years after conjugate vaccine introduction--eight states, 1998-2005.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2008 Feb; 57(6):144-8. PubMed ID: 18272956
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Licensure of 13-valent pneumococcal conjugate vaccine for adults aged 50 years and older.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2012 Jun; 61(21):394-5. PubMed ID: 22647745
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pneumococcal vaccination in adults: does it really work?
    Pitsiou GG; Kioumis IP
    Respir Med; 2011 Dec; 105(12):1776-83. PubMed ID: 21816596
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Direct and indirect effects of routine vaccination of children with 7-valent pneumococcal conjugate vaccine on incidence of invasive pneumococcal disease--United States, 1998-2003.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2005 Sep; 54(36):893-7. PubMed ID: 16163262
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Updated recommendations for prevention of invasive pneumococcal disease among adults using the 23-valent pneumococcal polysaccharide vaccine (PPSV23).
    ;
    MMWR Morb Mortal Wkly Rep; 2010 Sep; 59(34):1102-6. PubMed ID: 20814406
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pneumococcal polysaccharide vaccination for adults: new perspectives for Europe.
    Fedson DS; Nicolas-Spony L; Klemets P; van der Linden M; Marques A; Salleras L; Samson SI
    Expert Rev Vaccines; 2011 Aug; 10(8):1143-67. PubMed ID: 21810065
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of conjugate pneumococcal vaccines on the changing epidemiology of pneumococcal infections.
    Zangeneh TT; Baracco G; Al-Tawfiq JA
    Expert Rev Vaccines; 2011 Mar; 10(3):345-53. PubMed ID: 21434802
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pneumonia hospitalizations among young children before and after introduction of pneumococcal conjugate vaccine--United States, 1997-2006.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2009 Jan; 58(1):1-4. PubMed ID: 19145219
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The pneumococcal conjugate vaccine.
    Jacobson RM; Poland GA
    Minerva Pediatr; 2002 Aug; 54(4):295-303. PubMed ID: 12131865
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine for adults with immunocompromising conditions: recommendations of the Advisory Committee on Immunization Practices (ACIP).
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2012 Oct; 61(40):816-9. PubMed ID: 23051612
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Licensure of a 13-valent pneumococcal conjugate vaccine (PCV13) and recommendations for use among children - Advisory Committee on Immunization Practices (ACIP), 2010.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2010 Mar; 59(9):258-61. PubMed ID: 20224542
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The future of pneumococcal disease prevention.
    Rodgers GL; Klugman KP
    Vaccine; 2011 Sep; 29 Suppl 3():C43-8. PubMed ID: 21896352
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Progress in introduction of pneumococcal conjugate vaccine--worldwide, 2000-2008.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2008 Oct; 57(42):1148-51. PubMed ID: 18946462
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Serious invasive pneumococcal disease in young children: the importance of vaccination].
    Haveman LM; Geelen SP; Sanders EA; Wolfs TF
    Ned Tijdschr Geneeskd; 2002 Oct; 146(41):1917-20. PubMed ID: 12404904
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevenar experience.
    Arguedas A; Soley C; Abdelnour A
    Vaccine; 2011 Sep; 29 Suppl 3():C26-34. PubMed ID: 21896350
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A trial of a 9-valent pneumococcal conjugate vaccine in children with and those without HIV infection.
    Klugman KP; Madhi SA; Huebner RE; Kohberger R; Mbelle N; Pierce N;
    N Engl J Med; 2003 Oct; 349(14):1341-8. PubMed ID: 14523142
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [23-valent pneumococcal vaccine. Statement of the Consultive Committee of Immunizations on behalf of the Chilean Infectious Diseases Society: February 2010].
    Ripoll M E; Valenzuela B MT; Vergara F R; Abarca V K; Muñoz M A; Jiménez de la Jara J; Pinto C ME; Luchsinger F V
    Rev Chilena Infectol; 2010 Apr; 27(2):133-7. PubMed ID: 20556313
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.